E-mail a Wiley Online Library Link

Irina Lonskaya, Michaeline L. Hebron, Nicole M. Desforges, Alexander Franjie and Charbel E.-H. Moussa Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance EMBO Molecular Medicine 5

Version of Record online: 4 JUL 2013 | DOI: 10.1002/emmm.201302771

Thumbnail image of graphical abstract

Two FDA-approved tyrosine kinase inhibitor drugs, Bosutinib and Nilotinib, are shown to ameliorate Alzheimer's disease pathology in mouse models by increasing soluble parkin and leading to amyloid clearance and cognitive improvement.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field